Climacteric Complaints after Breast Cancer - Is HRT an Option?
Systemic estrogen depletion is the mechanism of action of most endocrine treatment strategies, and a common side effect of most chemotherapy regimens that are currently used to treat invasive breast cancer. The ensuing immediate and profound decline in estrogen levels is, however, often associated with considerable climacteric complaints. While oral estrogen add-back therapy is effective in alleviating menopausal symptoms, it is feared that it might also promote tumor cell growth. This concern is largely based on circumstantial evidence from large trials in healthy women, in which hormone replacement therapy (HRT) resulted in a slight, albeit significant, increase in incident breast cancer. In breast cancer survivors, however, evidence from studies remains controversial. Despite these caveats, the severity of symptoms and the lack of effective alternatives still cause many women to opt for HRT. Nevertheless, HRT cannot generally be recommended as first-line therapy for climacteric complaints in women with a history of breast cancer. It may, however, be a valid option for selected women with climacteric symptoms refractory to previous non-hormonal treatments. In these cases, an individualized risk-benefit analysis is imperative before treatment initiation, and a treatment duration of less than 5 years with intermittent withdrawal attempts should be aimed for.
Singer
Christian F
CF
Division of Special Gynecology, Department of OB/GYN, Medical University of Vienna, Austria.
J Clin Oncol. 2001 Apr 15;19(8):2357-63
11304788
J Reprod Med. 2005 Mar;50(3):155-65
15841927
J Natl Cancer Inst. 1999 Dec 1;91(23):2020-8
10580027
Breast. 2007 Dec;16 Suppl 2:S182-9
17983942
JAMA. 2007 Apr 4;297(13):1465-77
17405972
Clin Cancer Res. 2007 Jul 15;13(14):4185-90
17634547
J Natl Cancer Inst. 2008 Apr 2;100(7):475-82
18364505
Ann Intern Med. 2005 May 17;142(10):855-60
15897536
Maturitas. 2004 Aug 30;48 Suppl 1:S4-6
15337241
Obstet Gynecol. 2008 Jan;111(1):77-87
18165395
J Clin Oncol. 2007 Aug 10;25(23):3437-9
17592152
Clin Pharmacol Ther. 2008 Jan;83(1):160-6
17882159
J Natl Cancer Inst. 2005 Apr 6;97(7):533-5
15812079
Fertil Steril. 2004 Mar;81(3):617-23
15037411
Steroids. 2000 Oct-Nov;65(10-11):593-8
11108864
N Engl J Med. 2007 Apr 19;356(16):1670-4
17442911
Lancet. 2004 Feb 7;363(9407):453-5
14962527
Lancet Oncol. 2005 Sep;6(9):687-95
16129369
Lancet. 2003 Aug 9;362(9382):419-27
12927427
JAMA. 2002 Jul 17;288(3):321-33
12117397
J Clin Oncol. 2008 Mar 10;26(8):1260-8
18323549
BJOG. 2002 Oct;109(10):1109-14
12387462
Menopause. 2007 May-Jun;14(3 Pt 1):518-27
17224856
Obstet Gynecol. 1998 Oct;92(4 Pt 1):580-4
9764632
J Clin Endocrinol Metab. 2002 Jan;87(1):16-23
11788614
Maturitas. 2002 Aug 30;42(4):255-8
12191847
J Clin Oncol. 2008 Feb 10;26(5):753-8
18258983
BJOG. 2005 Feb;112(2):228-33
15663589